Patents by Inventor Paul Rennert

Paul Rennert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterologous polypeptide of the TNF family
    Patent number: 6875846
    Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.
    Type: Grant
    Filed: August 7, 2002
    Date of Patent: April 5, 2005
    Assignee: Biogen Idec MA Inc.
    Inventors: Paul Rennert, Jeffrey S. Thompson, Christine Ambrose, Teresa G. Cachero
  • Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
    Publication number: 20050008636
    Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
    Type: Application
    Filed: August 11, 2004
    Publication date: January 13, 2005
    Inventor: Paul Rennert
  • Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
    Patent number: 6719972
    Abstract: Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4 and the ligand is a monoclonal anti-CTLA4 antibody that binds to an epitope of CTLA4 distinct from the binding sites of B7-1 and B7-2. Upon binding of the antibody to CTLA4 on an activated T cell, in the presence of an antigenic signal, antigen specific apoptosis is induced. The invention also describes a novel natural CTLA4 ligand, distinct from B7-1 and B7-2, which mediates induction of apoptosis. Pharmaceutical compositions of anti-CTLA4 antibodies or other isolated CTLA4 ligands which can be administered to subjects to induce T cell apoptosis, thereby clonally deleting antigen specific. T cells, such as alloreactive T cells in transplantation situations or autoreactive T cells in autoimmune disorders, are also disclosed.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: April 13, 2004
    Assignees: Repligen Corporation, Dana-Farber Cancer Institute
    Inventors: John G. Gribben, Gordon J. Freeman, Lee M. Nadler, Paul Rennert, Cindy L. Jellis, Edward Greenfield, Gary S. Gray
  • Taci as an anti-tumor agent
    Publication number: 20040013674
    Abstract: A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10 % or more as compared to the absence of administering the TACI reagent.
    Type: Application
    Filed: June 23, 2003
    Publication date: January 22, 2004
    Inventors: Christine Ambrose, Jeffrey Thompson, Pascal Schneider, Paul Rennert
  • April receptor (BCMA) and uses thereof
    Publication number: 20030082175
    Abstract: A novel receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.
    Type: Application
    Filed: April 2, 2002
    Publication date: May 1, 2003
    Inventors: Pascal Schneider, Jeffrey Thompson, Teresa Cachero, Christine Ambrose, Paul Rennert
  • Heterologous polypeptide of the TNF family
    Publication number: 20030023038
    Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.
    Type: Application
    Filed: August 7, 2002
    Publication date: January 30, 2003
    Inventors: Paul Rennert, Jeffrey S. Thompson, Christine Ambrose, Teresa G. Cachero
  • Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
    Publication number: 20020015703
    Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
    Type: Application
    Filed: July 13, 2001
    Publication date: February 7, 2002
    Inventor: Paul Rennert